{
  "schema_version": 1,
  "slug": "semaglutide",
  "title": "Semaglutide",
  "canonical_url": "https://signalmeaning.com/signals/semaglutide/",
  "json_url": "https://signalmeaning.com/data/signals/semaglutide.json",
  "summary": "Pharma PR is selling a future of easy weight-loss fixes — call out manufacturers and outlets that conflate promising trial headlines with guaranteed access, and expose the real costs: supply bottlenecks, insurer denials, and out-of-pocket expenses for patients.",
  "why_now": "semaglutide appears to be trending because recent related news is clustering around: Novo Nordisk pens GLP-1 implant tech deal with Vivani Medical - Fierce Biotech; New weight loss pill beats oral Ozempic in major trial - ScienceDaily",
  "caveat": "Signal Type: Commerce / Consumer Demand",
  "collected_at": "Wed, 8 Jul 2026 07:40:00 -0700",
  "signal_type": "Commerce / Consumer Demand",
  "score": 88.0,
  "score_field": "adjusted_score",
  "state": "PUBLISH",
  "evidence": [
    "Novo Nordisk pens GLP-1 implant tech deal with Vivani Medical - Fierce Biotech",
    "New weight loss pill beats oral Ozempic in major trial - ScienceDaily"
  ],
  "provenance": {
    "record_id": "202607092141_signal_Quality-3-semaglutide",
    "batch_id": "202607092141",
    "input_files": {
      "Quality": "202607092141_signal_Quality.txt",
      "Musk": "202607092055_signal_Musk.txt",
      "Kurzweil": "202607092055_signal_Kurzweil.txt",
      "Jobs": "202607092055_signal_Jobs.txt",
      "Buffett": "202607092055_signal_Buffett.txt",
      "Bezos": "202607092047_signal_Bezos.txt"
    }
  }
}